UNSPSC 51283007: Pirlimycin hydrochloride

This classification denotes a lincosamide antibiotic with the molecular formula C17H31ClN2O5S.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8S09O559AQ, chemically known as l-threo-.alpha.-d-galacto-octopyranoside, methyl 7-chloro-6,7,8-trideoxy-6-(((4-ethyl-2-piperidinyl)carbonyl)amino)-1-thio-, monohydrochloride, monohydrate, (2s-cis)-, but more generally known as pirlimycin hydrochloride, which bears US NIH Compound Identifier 71997.

UNSPSC 51283007 Pirlimycin hydrochloride is a Commodity code for a specific pharmaceutical active ingredient, yet recent state and local opportunities show little activity directly aligned with this chemical compound. The code nominally describes pirlimycin hydrochloride, an antibiotic used primarily in veterinary medicine, but the solicitations posted under it involve different pharmaceutical products entirely — doxycycline hyclate, ciprofloxacin hydrochloride, naloxone, and drug deactivation systems. State and local governments do purchase pharmaceuticals through competitive bidding processes and cooperative purchasing vehicles, but the specific opportunities recorded here do not reflect procurement of pirlimycin hydrochloride itself. Issuing bodies include state health departments and county health authorities, which use piggyback contracts and invitation-for-bid processes to source pharmaceutical supplies for public health programs and emergency response initiatives.

The geographic spread of recorded activity spans Illinois and Florida, with the Illinois Department of Public Health awarding a piggyback pharmaceutical contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (solicitation 26482DPHPREPDB53392, now closed), and Seminole County, Florida releasing an IFB for naloxone and drug deactivation systems with a due date of July 26, 2026 (solicitation IFB60459723LAS). The Illinois contract, valued at $2,999,999.11 over 12 months with two optional renewal years, supplied doxycycline hyclate and ciprofloxacin hydrochloride in bulk packages; the Seminole County procurement requested 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries and a two-year initial term plus optional one-year renewal. Neither opportunity actually solicited pirlimycin hydrochloride, indicating a potential code-classification mismatch in the state and local procurement database rather than active market demand for this specific pharmaceutical compound.